{"product_id":"harvard-dementia-a-comprehensive-update-2026","title":"Harvard Dementia A Comprehensive Update 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: neurologists, psychiatrists, and primary care physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eNew this year will be a discussion of recently approved disease-modifying therapies for AD. Lectures and programs also provide education on special topics in dementia such as managing problem behaviors, disclosure of diagnosis and risk, chronic traumatic encephalopathy, caregiving in dementia, pain, palliation, hospice care, medicolegal issues, capacity and competence, undue influence, driving, long-term\/ nursing home care, delirium and dementia, neuroethics, advanced care planning, and neuropsychology of aging.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eDescribe current understanding of epidemiology, risk factors, pathobiology, societal costs, clinical differences, gaps in knowledge, and challenges in distinguishing and managing the spectra of normal cognitive aging, mild cognitive impairment (MCI), Alzheimer’s disease (AD), and other neurodegenerative dementias.\u003c\/p\u003e\n\u003cp\u003eSummarize tiered diagnostic and management approaches, including the new Clinical Practice Guidelines sponsored by the Alzheimer’s Association for the diagnostic evaluation of patients with cognitive impairment. Summarize current and future experimental therapeutics strategies under consideration for risk reduction, prevention, diagnosis and treatment of the AD spectrum.\u003c\/p\u003e\n\u003cp\u003eDifferentiate, based on neuropathology, affected neural systems, clinical criteria and biomarkers, AD and its atypical variants from other common dementias including Dementia with Lewy Bodies (DLB), Vascular Cognitive Impairment (VCI)\/Vascular-Ischemic Dementia, Frontotemporal Degeneration (FTD), Parkinson’s disease with Dementia (PDD), Parkinson’s-Plus Syndromes and less common dementias.\u003c\/p\u003e\n\u003cp\u003eIdentify and explain the importance of evidence-based and coordinated individualized approaches to the evaluation and management of MCI, AD and neurodegenerative dementias that stress combining: (i) early and accurate detection, assessment and monitoring; (ii) psycho-education and non-pharmacological interventions; (iii) pharmacological strategies; and (iv) caregiver, psychosocial\/environmental, quality of life, ethical, medico-legal and end-of-life considerations.\u003c\/p\u003e\n\u003cp\u003eApply data-supported diagnostic, behavioral, pharmacological, and environmental strategies, including appropriate and tiered use of cognitive tests\/measures, labs, and imaging studies\/biomarkers; and delineation of expectations, roles (i.e., indications and benefits), cautions (i.e., risks, side-effects, warnings) and treatment nuances in the interdisciplinary management of CI, AD and neurodegenerative dementias.\u003c\/p\u003e\n\u003cp\u003eExplain the roles of office-based screening instruments, mental status exam (MSE) and neuropsychological evaluation in the diagnosis and management of dementia; develop efficient approaches to MSE and use of screening instruments (e.g. MOCA); and interpret and compare cognitive testing\/neuropsychological performance patterns for different conditions and clinical syndromes (e.g. MCI, AD, FTD, primary progressive aphasias, posterior cortical atrophy, DLB).\u003c\/p\u003e\n\u003cp\u003eUtilize appropriate laboratory tests, imaging studies, and neuropsychological testing for the diagnosis of dementia in clinical practice; incorporate appropriate use of clinical biomarkers (e.g. CSF a-beta\/tau, MRI, FDG- and Amyloid-PET) in evaluation of neurodegenerative dementias to differentiate AD and non-AD processes; and explain clinical versus research use, and apply appropriate use criteria\/guidelines for the clinical use of biomarkers in the diagnosis of AD-like syndromes.\u003c\/p\u003e\n\u003cp\u003eApply data-supported pharmacologic management strategies including the roles (i.e., indications and benefits), cautions (i.e., risks, side-effects, warnings) and potential alternatives to using cholinesterase inhibitors, memantine, antipsychotics and antidepressants in dementia and AD.\u003c\/p\u003e\n\u003cp\u003eDiscuss the important role, and the challenges and risks caregivers face; describe strategies to help dementia caregivers cope and better care for themselves and for patients with dementia including psychosocial counseling, community support resources, and respite care.\u003c\/p\u003e\n\u003cp\u003eDevelop appropriate practices concerning medico-legal and safety issues surrounding patients with dementia, including capacity with regards to medical care, finances, contracts, independent living, and driving; and integrate medico-legal and safety practices to support and safeguard patients and families, and the public-at-large.\u003c\/p\u003e\n\u003cp\u003eDescribe issues related to dementia neuroethics, and implement effective practices in the long-term care\/nursing-home environment and in end-stage dementia regarding medical, legal, and ethical issues including recognition and treatment of delirium\/encephalopathy and pain, providing palliation and hospice care, and managing end-of-life issues related to dementia.\u003c\/p\u003e\n\u003cp\u003eDemonstrate neural processes and functional networks that support perception and cognitive systems including memory, language, attentional, frontal\/executive, visuo-spatial, and motor systems.\u003c\/p\u003e\n\u003cp\u003eDistinguish pre-clinical AD, MCI due to AD\/prodromal AD, and AD dementia phases.\u003c\/p\u003e\n\u003cp\u003eIdentify delirium\/encephalopathy and Chronic Traumatic Encephalopathy(CTE) as a dementia risks or entities.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eBest for neurologists, psychiatrists, and primary care physicians who want updates on dementia biomarkers, treatments, and patient care.\u003c\/p\u003e\n\u003cp\u003eSpecialty Physicians, Psychologists, Physician Assistants, Nurse Practitioners, Nurses, Primary Care Physicians, Social Workers, and Others.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eIntroduction to the Course\u003c\/p\u003e\n\u003cp\u003eHuman Cognition An Overview\u003c\/p\u003e\n\u003cp\u003eMemory Systems \u0026amp; Amnesia\u003c\/p\u003e\n\u003cp\u003eNeuropathology of AD ADRD A Guide forPracticing Clinicians\u003c\/p\u003e\n\u003cp\u003eFrom Proteinopathies to Neuroimaging \u0026amp; Biomarkers in AD ADRD Primer on Practice and Advances\u003c\/p\u003e\n\u003cp\u003eAlzheimer’s Disease \u0026amp; Related Dementias Global Perspectives and Opportunities\u003c\/p\u003e\n\u003cp\u003eClinical Use of Blood Biomarkers in 2026 and Beyond\u003c\/p\u003e\n\u003cp\u003ePanel Discussion and Q\u0026amp;A Alireza Atri; Brad Dickerson\u003c\/p\u003e\n\u003cp\u003eAD Dementia Practical Evaluation \u0026amp; Managementin Clinical Practice\u003c\/p\u003e\n\u003cp\u003eMild Cognitive Impairment Prodromal AD and Beyond\u003c\/p\u003e\n\u003cp\u003eAdvances in AD Experimental Therapeutics + Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eNeuropsychology of Aging\u003c\/p\u003e\n\u003cp\u003eAttentional and Executive Systems – Don’t Leave Home without Them\u003c\/p\u003e\n\u003cp\u003eFrontotemporal Dementias Focus on Behaviorall Executive Variants\u003c\/p\u003e\n\u003cp\u003eLanguage Systems \u0026amp; Aphasia-predominant Dementia Syndromes\u003c\/p\u003e\n\u003cp\u003eUpdates on Vascular Cognitive Impairment \u0026amp; Dementia\u003c\/p\u003e\n\u003cp\u003ePanel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eLewy Body Disease, and Parkinsonian \u0026amp; Sensorimotorpredominant Dementias\u003c\/p\u003e\n\u003cp\u003eAssessment of Cognition in Clinical Practice\u003c\/p\u003e\n\u003cp\u003ePractical Compensatory Strategies for Cognitive Decline\u003c\/p\u003e\n\u003cp\u003eAssessment of Daily Function and Neuropsychiatric Symptoms Behavior and Staging of Dementia in Practice\u003c\/p\u003e\n\u003cp\u003eCased-based Discussion of Lecanemab and Donanemab\u003c\/p\u003e\n\u003cp\u003ePanel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eNon-Pharmacological Approaches to Neuropsychiatric Symptoms and Problem Behaviors in Dementia\u003c\/p\u003e\n\u003cp\u003ePharmacological Management of Behavioral Problems in Dementia\u003c\/p\u003e\n\u003cp\u003ePractical \u0026amp; Ethical Considerations for Disclosure of Demetia-Related Diagnosis and Risk\u003c\/p\u003e\n\u003cp\u003eCaregiving in Dementia Impact, Consequences \u0026amp; Opportunities\u003c\/p\u003e\n\u003cp\u003ePanel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eCommunity Advocacy and Activism For Dementias\u003c\/p\u003e\n\u003cp\u003eChronic Traumatic Encephalopathy (CTE) \u0026amp; Dementia\u003c\/p\u003e\n\u003cp\u003eDelirium, Encephalopathies and Uncommon Dementias\u003c\/p\u003e\n\u003cp\u003ePanel Discussion, Q\u0026amp;A and Conclusions\u003c\/p\u003e\n\u003cp\u003eDementia \u0026amp; The Law Clinical Pearls on Testamentary Capacity and Undue Influence\u003c\/p\u003e\n\u003cp\u003ePrinciples \u0026amp; Practice of Mental Capacity and Competence in Dementia From Finances to Firearms\u003c\/p\u003e\n\u003cp\u003eDriving, Home \u0026amp; Community Safety and Dementia\u003c\/p\u003e\n\u003cp\u003eAdvance Care Planning \u0026amp; Management of End-stage Dementia, Pain, Palliation \u0026amp; Hospice in Long-Term Care\u003c\/p\u003e\n\u003cp\u003ePanel Discussion, Q \u0026amp; A, and conclusions\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405754454212,"sku":null,"price":104.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Dementia-A-Comprehensive-Update-2026.jpg?v=1784215729","url":"https:\/\/medicalcoursespro.com\/products\/harvard-dementia-a-comprehensive-update-2026","provider":"Medicalcoursespro","version":"1.0","type":"link"}